Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony J Scott

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
American Journal of Medical Genetics. Part A|August 22, 2020
A cautionary tale of pyridoxine toxicity in cystathionine beta-synthase deficiency detected by two-tier newborn screening highlights the need for clear pyridoxine dosing guidelinesElizabeth G Ames, Anthony J Scott, Kara B Pappas, et al.
Familial Cancer|June 7, 2020
Germline variants discovered in lymphoma patients undergoing tumor profiling: a case seriesAnthony J Scott, Molly C Tokaz, Michelle F Jacobs, et al.
Leukemia & Lymphoma|November 16, 2020
Clinical application of next generation sequencing in lymphomaAnthony J Scott, Molly C Tokaz, Maryann Shango, et al.
Scientific Reports|January 3, 2024
Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancerCindy Y Jiang, Lili Zhao, Michael D Green, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
American Journal of Medical Genetics. Part A|August 22, 2020
A cautionary tale of pyridoxine toxicity in cystathionine beta-synthase deficiency detected by two-tier newborn screening highlights the need for clear pyridoxine dosing guidelinesElizabeth G Ames, Anthony J Scott, Kara B Pappas, et al.
Familial Cancer|June 7, 2020
Germline variants discovered in lymphoma patients undergoing tumor profiling: a case seriesAnthony J Scott, Molly C Tokaz, Michelle F Jacobs, et al.
Leukemia & Lymphoma|November 16, 2020
Clinical application of next generation sequencing in lymphomaAnthony J Scott, Molly C Tokaz, Maryann Shango, et al.
Scientific Reports|January 3, 2024
Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancerCindy Y Jiang, Lili Zhao, Michael D Green, et al.
Pageof 1